Effects of nebulized NG‐nitro‐L‐arginine methyl ester in patients with hepatopulmonary syndrome
Federico P. Gómez, Joan A. Barberà, Josep Roca, Felip Burgos, Concepción Gistau, Robert Rodríguez‐Roisin – 20 April 2006 – Enhanced pulmonary production of nitric oxide (NO) has been implicated in the pathogenesis of hepatopulmonary syndrome (HPS). NO inhibition with NG‐nitro‐L‐arginine methyl ester (L‐NAME) in both animals and humans with HPS has improved arterial hypoxemia. We assessed the role of enhanced NO production in the pathobiology of arterial deoxygenation in HPS and the potential therapeutic efficacy of selective pulmonary NO inhibition.